Vaxcyte, Inc.

PCVXSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1649094

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$332.3M	$169.5M	$78.4M	$73.6M	$45.6M
Operating Expenses	$468.0M	$232.3M	$103.7M	$89.6M	$54.2M
Operating Income (Loss)	-$468.0M	-$232.3M	-$103.7M	-$89.6M	-$54.2M
Interest Expense	—	—	$7.0K	$7.0K	$40.0K
Nonoperating Income (Expense)	$65.8M	—	—	—	—
Income Tax Expense (Benefit)	$0.00	—	—	—	—
Net Income (Loss) Attributable to Parent	-$402.3M	-$223.5M	-$100.1M	-$89.2M	-$50.3M
Earnings Per Share, Basic	-$4.14	-$3.44	-$1.93	-$3.02	—
Earnings Per Share, Diluted	-$4.14	-$3.44	-$1.93	-$3.02	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$3.5B	$1.4B	$1.0B	$324.3M	$392.8M
Assets, Current	$1.8B	$1.1B	$942.6M	$256.3M	$389.0M
Cash and Cash Equivalents, at Carrying Value	$397.5M	$834.7M	$834.7M	$386.2M	$59.0M
Liabilities	$205.5M	$167.4M	$52.6M	$40.3M	$47.0M
Liabilities, Current	$140.2M	$145.3M	$40.5M	$28.7M	$46.9M
Accounts Payable, Current	$48.5M	$14.6M	$9.8M	$6.8M	$29.8M
Stockholders' Equity Attributable to Parent	$953.6M	$284.0M	$345.8M	-$106.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$296.8M	-$170.6M	-$121.4M	-$46.6M	-$47.1M
Net Cash Provided by (Used in) Investing Activities	-$773.3M	$74.6M	-$212.3M	-$1.1M	-$1.2M
Net Cash Provided by (Used in) Financing Activities	$639.8M	$861.5M	$17.8M	$374.9M	$41.6M
Payments to Acquire Property, Plant, and Equipment	$16.1M	$5.8M	$6.6M	$1.2M	$1.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)